Will ATAI dose the first patient in both BPL-003 Phase 3 pivotal trials by 2026-09-30?

Management guided Q2 2026 FPD at the February 2026 EoP2 meeting. The 'both trials dosed by Q3 2026' filter requires first trial FPD ~75% conditional, second trial FPD within 60-90 days ~70% conditional. Joint probability 0.75 x 0.70 = 0.525 before adjustment. Adjust upward for Breakthrough Therapy + debt-free balance sheet + existing Phase 2b infrastructure at 38 sites: +0.1. Lands at 0.62. Slight premium to pure base rate because management has every incentive to deliver post-341% rally, and the EoP2 meeting timing was a public commitment.

Biotech Phase 3 FPD base rate at the initially-guided quarter is approximately 65-75%. For the 'both trials by end of Q3 2026' constraint, I treat the second trial as a meaningful additional hurdle. DEA Schedule I protocol friction and CRO selection post-EoP2 mean first FPD realistically lands Q3 2026 (not Q2 as guided) for ~30-40% of programs, and in those cases second trial typically slips to Q4. Probability both are dosed by 2026-09-30 lands at 0.58 — slightly below pure base rate because dual-trial timing is the binding constraint, not regulatory clearance.

I weight upward for program-specific factors: (a) Phase 2b already ran across 38 sites in 6 countries so infrastructure continuity is exceptional for a post-EoP2 Phase 3 launch, (b) Beckley merger consolidated BPL-003 under one entity eliminating coordination friction, (c) Breakthrough Therapy Designation enables IND amendment and protocol feedback acceleration. Management's specific Q2 2026 guidance was conservative relative to the Feb 2026 EoP2 timing. Three-factor product: 0.80 P(first FPD by Q3) x 0.80 P(second FPD by Q3 given first) = 0.64. Round to 0.65.

Three-stage decision tree: (1) first trial FPD by Q3 2026 ~75%, (2) second trial FPD within 60-90 days ~75%, (3) public disclosure of both before 2026-09-30 ~90% (biotechs actively publicize FPD events). Joint 0.75 x 0.75 x 0.90 = 0.506. Adjust upward for Breakthrough status + validated Phase 2b infrastructure: +0.10. Lands at approximately 0.60. I treat dual-trial timing as the binding filter.

Conservative stance. Biotech timeline slippage is historically 30-50%, and management guidance has a known optimism bias. Phase 3 psychiatric trial initiation involves SPA negotiation, CRO onboarding, site activation, IRB approvals, and DEA Schedule I clearances — each with 2-8 week variance. Even Breakthrough-designated programs with strong Phase 2b data slip first FPD ~30% of the time. Second trial slip rate adds another layer. Base probability 0.55 — slightly below coin-flip between on-time and one-quarter slip.

Balanced view. The EoP2 meeting closed Feb 2026 with design feedback — this is a meaningful regulatory green light. Management explicitly guided Q2 2026 FPD. Post-rally incentive alignment is strong (stock price depends on execution credibility). But dual-trial timing is genuinely difficult — simultaneous FPD is rare; staggered launches typically have 30-60 day gaps. Probability of both dosed by 2026-09-30 lands at 0.62, reflecting both program-specific tailwinds and the dual-trial compression.

Breakthrough biotechs with completed EoP2 meetings hit initial guided quarter ~65-75% of the time. Dual-trial requirement compresses to 50-65%. Center of range 0.60.

Management guided Q2 2026 FPD. Q3 2026 deadline adds one quarter of cushion. Most well-funded post-EoP2 programs hit 1-quarter cushion ~70%. Second trial drag -10%. Net 0.58.

Program-specific factors (Phase 2b 38-site infrastructure, Breakthrough status, debt-free balance sheet, single-asset management focus) justify above-base-rate probability. Anchor at 0.63 — modestly above pure biotech base rate of 0.55-0.60.